(Q52604946)

4 May 2018

title

Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. (English)

1 reference

4 May 2018

1 reference

Zhe Wang

1

1 reference

4 May 2018

Wai-Keung Chui

series ordinal

2

1 reference

4 May 2018

Paul C Ho

series ordinal

3

1 reference

4 May 2018

publication date

6 November 2010

1 reference

4 May 2018

published in

Pharmaceutical Research

1 reference

4 May 2018

volume

28

1 reference

4 May 2018

issue

3

1 reference

4 May 2018

page(s)

585-596

1 reference

4 May 2018

Endothelial cells and VEGF in vascular development

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Antiangiogenesis to treat cancer and intraocular neovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Drug delivery with carbon nanotubes for in vivo cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0308-2

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

21 January 2018

1 reference

12 December 2020

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically

1 reference

12 December 2020

Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.

1 reference

12 December 2020

10.1007/S11095-010-0308-2

Identifiers

DOI

1 reference

4 May 2018

PubMed ID

21057857

1 reference

4 May 2018